Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition

Novo Nordisk (NVO) stock plunged over 21% after the company sharply cut its full-year sales and operating profit forecasts for the second time this year, attributing the revised outlook to weaker-than-expected second-half performance for Wegovy and Ozempic amid intensifying competition from rivals like Eli Lilly and compounded GLP-1s. The updated guidance now projects sales growth of 8%-14% (down from 13%-21%) and operating profit growth of 10%-16% (down from 16%-24%), reflecting significant market share challenges, including Eli Lilly's Zepbound surpassing Wegovy in US prescriptions.

Analysis

Novo Nordisk (NVO) experienced a significant market re-rating, with its stock plunging over 21% following a severe cut to its full-year financial forecasts. The company reduced its expected sales growth to 8%-14% from a prior 13%-21% and slashed its operating profit growth outlook to 10%-16% from 16%-24%. This marks the second downward revision this year, signaling deep-seated operational and competitive challenges rather than a one-time issue. Management explicitly attributes the weakness to intensifying competition from rival drugmakers and compounded GLP-1s, coupled with a slower-than-anticipated expansion of the weight-loss drug market. The competitive pressure is substantiated by data showing Eli Lilly's (LLY) Zepbound surpassed Wegovy in US prescriptions in March and demonstrated superior efficacy in a head-to-head trial. This erosion of market leadership is reflected in NVO's stock performance, which is down over 55% in the last year, and has precipitated a leadership change with a new CEO set to take over in August. The market's divergent reaction, with competitor LLY falling only 5% and Hims & Hers Health (HIMS) rising over 2.5%, indicates a flight to quality and a re-allocation of capital toward perceived winners in the segment.

Key Decisions for Investors

• Given the second consecutive guidance cut and clear evidence of market share erosion to a competitor with a more effective product, investors should exercise extreme caution with Novo Nordisk and re-evaluate the thesis for holding a long position.
• The market dislocation presents a potential relative value trade; consider assessing competitors like Eli Lilly, which is solidifying its market leadership, and smaller players like Hims & Hers Health, which are benefiting from the shifting competitive landscape.
• Closely monitor incoming prescription data for Wegovy versus Zepbound, as well as any strategic announcements from the new CEO, as these will be the primary indicators of a potential stabilization or continued decline for Novo Nordisk.